Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:41:00.000Z.
Calculation as of: 2026-10-06T22:41:00.000Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 412370d08cb3fb7a3c2e4d636897a8ea9259835d42853a062d33098765049a4f
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$369.50M
PE Ratio
N/A
TTM Avg
20.42
3Y Avg
20.42
5Y Avg
20.42
Market Cap
$359.53M
PE Ratio
N/A
TTM Avg
170.63
3Y Avg
170.63
5Y Avg
170.63
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canopy Growth Corporation (CGC) | $376.01M | N/A | N/A | N/A | N/A |
| Zura Bio Limited (ZURA)vs › | $376.19M | N/A | N/A | N/A | N/A |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $374.50M | N/A | N/A | N/A | N/A |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | N/A | 157.27 | 122.07 | 183.95 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | N/A | 20.42 | 20.42 | 20.42 |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | N/A | 13.34 | 13.34 | 21.63 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | N/A | 170.63 | 170.63 | 170.63 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 25.65 | 24.97 | 28.19 | 31.91 |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2016-03-31 | 4925.83 |
| 2016-03-30 | 4913.51 |
| 2016-03-29 | 4805.09 |
| 2016-03-28 | 4866.69 |
| 2016-03-24 | 4849.44 |
| 2016-03-23 | 4753.34 |
| 2016-03-22 | 5093.39 |
| 2016-03-21 | 5093.39 |
| 2016-03-18 | 5157.46 |
| 2016-03-17 | 5147.60 |
| 2016-03-16 | 4893.80 |
| 2016-03-15 | 4938.15 |
| 2016-03-14 | 5098.32 |
| 2016-03-11 | 5238.78 |
| 2016-03-10 | 5305.31 |
| 2016-03-09 | 5381.70 |
| 2016-03-08 | 5329.95 |
| 2016-03-07 | 5396.48 |
| 2016-03-04 | 5455.62 |
| 2016-03-03 | 5381.70 |
| 2016-03-02 | 5485.19 |
| 2016-03-01 | 5507.37 |
| 2016-02-29 | 5376.77 |
| 2016-02-26 | 5297.92 |
| 2016-02-25 | 5251.10 |
| 2016-02-24 | 5297.92 |
| 2016-02-23 | 5576.36 |
| 2016-02-22 | 5169.78 |
| 2016-02-19 | 4965.26 |
| 2016-02-18 | 4952.93 |
| 2016-02-17 | 4994.83 |
| 2016-02-16 | 4854.37 |
| 2016-02-12 | 4807.55 |
| 2016-02-11 | 4583.31 |
| 2016-02-10 | 4612.88 |
| 2016-02-09 | 4674.49 |
| 2016-02-08 | 4516.78 |
| 2016-02-05 | 4672.02 |
| 2016-02-04 | 4765.66 |
| 2016-02-03 | 4731.16 |
| 2016-02-02 | 4607.95 |
| 2016-02-01 | 4785.37 |
| 2016-01-29 | 4718.84 |
| 2016-01-28 | 4674.49 |
| 2016-01-27 | 4708.98 |
| 2016-01-26 | 4684.34 |
| 2016-01-25 | 4672.02 |
| 2016-01-22 | 4731.16 |
| 2016-01-21 | 4657.24 |
| 2016-01-20 | 4534.03 |
| 2016-01-19 | 4561.14 |
| 2016-01-15 | 4595.63 |
| 2016-01-14 | 4780.44 |
| 2016-01-13 | 4810.01 |
| 2016-01-12 | 4930.76 |
| 2016-01-11 | 4948.01 |
| 2016-01-08 | 4861.76 |
| 2016-01-07 | 4519.24 |
| 2016-01-06 | 4940.61 |
| 2016-01-05 | 5130.35 |
| 2016-01-04 | 5150.07 |
